The Pharmaceutical Market in Argentina and Angola

on Monday, 9 June 2014 include new market research report " The Pharmaceutical Market in Argentina and Angola: Industry Size, Shares, Growth, Analysis, Trends And Forecast" to its huge collection of research reports.

Argentina's Pharmaceutical Market:
Argentina's pharmaceutical market will become increasingly unattractive to multinational pharmaceutical companies, as the double-digit market growth has been mainly driven by the high inflation rate. The strict currency and import restrictions, as well as poor regulatory regime, have further undermined foreign drugmakers' revenue-generating opportunities. A potential currency devaluation in the future will increase Argentina's export of medicines to a certain extent, if the country's structural distorting policies have not eroded its local pharmaceutical production capacity. View Full Report with TOC at:

Argentina remains at the eighth place in BMI's RRRs in Q113. However, the poor regulatory regime and high inflation rate are still challenging for the multinational drug companies. The deteriorating business environment and protectionist policies will also have a negative impact on the market. Argentina's pharmaceutical market is expected to grow at double-digit rates through to 2016 in local currency terms, largely due to inflation.

Angola's Pharmaceutical Market:
Since re-election in August 2012, incumbent President Dos Santos has promised considerable investment in Angola's healthcare and pharmaceutical market. With plans for new hospitals announced - including one expansion financed with Chinese funds - as well as the creation of mini laboratories to conduct quality checks on drugs, the government is taking steps to improve healthcare provision. But between these few, concrete projects, many vague proposals remain, with little detail around how they will be implemented or funded. Revised historical trade data has led to a sharp downward revision of the size of Angola's pharmaceutical market this quarter. These new figures have also led to a reduction of the size of Angola's healthcare market - although to a lesser degree. Given the unreliability of official figures, we will continue to monitor trade data and will adjust Angola's market size accordingly. View Full Report with TOC at:

Angola's Pharmaceutical Risk/Reward Rating (RRR) score for Q213 is unchanged from the previous quarter. This is also the case for all other countries in BMI's proprietary system that ranks pharmaceutical markets according to attractiveness to multinational drugmakers. A minor re-weighting of one of the RRR components is being implemented to improve the tool, and the adjusted scores for all markets will be published in theQ313 updates of the Pharmaceuticals & Healthcare reports. Angola has a RRR score of 34.8 out of 100, making it the 26thmost attractive pharmaceutical market in Middle East and Africa.

Browse More Reports related to Pharmaceuticals:

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

About Us:

ResearchMoz ( ) is the one stop online destination to find and buy market research reports. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. We provide the market context, competitor insight and future trends needed for strategic planning.

For More Information Kindly Contact: 
Mrs.Sheela AK
Toll Free: 866-997-4948


Post a Comment